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ABSTRACT
RNA polymerase (pol) III occurs in two forms, con-
taining either the POLR3G subunit or the related par-
alogue POLR3GL. Whereas POLR3GL is ubiquitous,
POLR3G is enriched in undifferentiated cells. Deple-
tion of POLR3G selectively triggers proliferative ar-
rest and differentiation of prostate cancer cells, re-
sponses not elicited when POLR3GL is depleted. A
small molecule pol III inhibitor can cause POLR3G
depletion, induce similar differentiation and sup-
press proliferation and viability of cancer cells. This
response involves control of the fate-determining
factor NANOG by small RNAs derived from Alu short
interspersed nuclear elements. Tumour initiating ac-
tivity in vivo can be reduced by transient exposure
to the pol III inhibitor. Untransformed prostate cells
appear less sensitive than cancer cells to pol III de-
pletion or inhibition, raising the possibility of a ther-
apeutic window.
INTRODUCTION
Whereas pol II transcribes all protein-encoding genes, pol
III synthesizes short non-coding RNAs, such as tRNA
and 5S rRNA (1). Pol III is unique in having alterna-
tive paralogues of one of its subunits, POLR3G (RPC7,
RPC32) and POLR3GL (RPC7L, RPC32), which share
49% amino acid identity (2,3). POLR3GL is ubiquitous,
whereas POLR3G is enriched in stem and cancer cells (2,3).
A striking decrease in expression of POLR3G when hu-
man embryonic stem cells (hESC) differentiate provoked
the suggestion that it may be required for maintenance of
pluripotency, perhaps through expression of specific pol
III products (4). Independent studies confirmed the enrich-
ment of POLR3G in hESC lines, as well as human in-
duced pluripotent stem cells and very early mouse embryos,
and also its down-regulation during differentiation (2,5,6).
This expression pattern is consistent with evidence that the
gene encoding POLR3G is directly bound and activated
by NANOG and OCT4A, master regulators of stem cell
pluripotency (5). Notably, hESC overexpressing POLR3G
are resistant to differentiation (5,7). Conversely, RNAi of
POLR3G causes hESC to lose stem cell markers and dif-
ferentiate (5,7). POLR3G binds to telomerase reverse tran-
scriptase (TERT), a protein that enhances the prolifera-
tive capacity of many stem and cancer cell types (6). The
data suggest that POLR3G may suppress cell differentia-
tion and therebymaintain proliferative capacity and pheno-
typic plasticity, features associated with aggressive cancers.
Indeed, POLR3Gcan be induced by viral and cellular onco-
genes and increase the growth of xenograft tumours in mice
(2,6,8). These observations raise the possibility that target-
ing POLR3G might trigger differentiation, thereby reduc-
ing tumourigenicity. To test this, we used the PC-3 cell line,
which was isolated directly from a prostate cancer metasta-
sis (9) and displays rapid androgen-independent growth that
mimics aggressive, therapy-resistant disease (10). Themain-
stay treatment for prostate cancer with metastatic spread is
androgen deprivation, but most patients eventually develop
resistance (11–13), a condition termed castrate-resistant
prostate cancer (CRPC). This often involves differentia-
tion to an androgen-independent neuroendocrine pheno-
type with poor prognosis (14–16). Because of the unmet
clinical need for effective strategies to combat androgen-
independent prostate cancer, we explored the influence of
POLR3G in a model that is refractory to standard treat-
ment. We find that depleting POLR3G can indeed promote
differentiation and suppress proliferation and viability of
prostate cancer cells.
MATERIALS AND METHODS
Cell culture and treatments
Cell lines were cultured in either RPMI medium contain-
ing 10% fetal calf serum and 5 mM glutamine (PNT2C2,
BPH1 and DU145) or Ham’s F12 medium containing 7%
fetal calf serum and 5 mM glutamine (PC-3). Normal pri-
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mary prostate epithelial cells (CC-2555) were purchased
from Lonza and cultured in prostate epithelial cell growth
mediumbulletkit (Lonza, CC-3166). Prostate tissue was ob-
tained with informed consent from patients (Table 1) un-
dergoing radical prostatectomy or trans-urethral resection
for prostate cancer (TURP), with approval from the lo-
cal Research Ethics Committee (07/H1304/121). Epithe-
lial cultures were prepared as previously described (17) and
cultured in complete keratinocyte growth medium supple-
mented with 2 ng/ml leukaemia inhibitory factor, 2 ng/ml
stem cell factor and 100 ng/ml cholera toxin. Patient sam-
ples were all anonymized.
All cells were grown at 37◦C in a humidified atmosphere
of 95% air and 5% CO2. After plating, cells were allowed to
attach overnight before treatment with DMSO vehicle (‘un-
treated’) or the indicated concentration of ML-60218 (Cay-
man Chemical, Michigan, USA). RNAi was performed
with Lipofectamine 3000 (Thermo Fisher) according to the
manufacturer’s instructions, using Silencer Select siRNAs
(Thermo Fisher).
RT-PCR
Total RNA was extracted using Trizol (Thermo Fisher),
according to the manufacturer’s protocol and treated with
DNAse I (New England Biolabs) for 15 min at 37◦C. RNA
was quantified using a Nanodrop spectrophotometer and
purity assessed using the 260/280 ratio. 0.5g RNAwas re-
verse transcribed in a 20 l reaction volume using random
hexamers and incubation with 200 U Superscript IV (Life
Technologies) at 55◦C for 30min. RT-qPCRwas performed
in a 20 l reaction volume using 37.5 ng cDNAmixed with
1× Fast SYBR Green Master Mix (Applied Biosystems)
and 5 M of the primer sequences listed in Table 2 on a
QuantStudio 3 Real-Time PCR System (Applied Biosys-
tems). Denaturation step was performed at 95◦C for 10 s
with annealing at 60◦C for 20 s and extension at 72◦C for 15
s (40 cycles). Melt curve analysis was performed to ensure
specificity of PCR products. qPCR analysis was carried out
using Experiment Manager software provided by Thermo
Fisher. The delta-delta Ct method was used for relative
quantification, with normalization to the constitutively-
expressed mRNA encoding acidic ribosomal phosphopro-
tein (ARPP) P0. NANOG-Alu-Sx primers recognize the T1
transcript described by Morales-Hernandez (18); primers
for the T2 transcript from the same locus (18) gave very sim-
ilar results to those shown.
Northern blot
5 g of total RNA, prepared as above, was added to an
equal volume of 2× loading buffer (NEB B0363S), heated
to 95◦C, snap cooled on ice then run on a 10% acry-
lamide (19:1), 7.5 M urea, 1× TBE denaturing gel. Samples
were transferred to Zeta probe GT membrane (1620196,
Biorad) and UV-crosslinked using a Stratalinker on au-
tocrosslink setting. Blots were hybridised inDIGEasy-hybe
buffer (Sigma) in a hybridization oven and then sequentially
probed with DIG-labelled probes designed to U2 snRNA
(loading control) and tRNAiMet. Signal was developed us-
ing the DIG wash and block buffer set (Sigma) and anti-
digoxigenin AP-conjugate at 1/100 000 dilution (Sigma)
and CDP-star detection solution (Roche). Probe for U2
snRNA was prepared using PCR DIG probe synthesis kit
(Sigma) and hybridized at 40◦C. Probes for tRNAiMet and
for forward and reverse NANOG-Alu-Sx riRNA were 3′
NHS-ester DIG-labelled oligos (IDT) hybridized at 25◦C.
Membranes were exposed to Amersham Hyperfilm ECL,
films scanned and then analysed by ImageJ software. Av-
erage fold changes of tRNAiMet in response to ML-60218
were calculated after normalization against U2 snRNA and
based on values from five independent experiments.
Western blot
Total cellular protein was extracted using CytoBuster Pro-
tein Extraction Reagent (Merck Millipore). Protein con-
centrations were determined using the Pierce BCA Pro-
tein Assay Kit (Life Technologies). Proteins were fraction-
ated by SDS-PAGE and transferred to nitrocellulose mem-
branes, before probing with antibodies sc-28712 against
POLR3G (Santa Cruz Biotechnology), HPA027288 against
POLR3GL (Atlas Antibodies), 1900 against POLR3A (19)
and sc-1615 against actin (Santa Cruz Biotechnology),
ab53025 against NSE (Abcam), ab8049 against SYP (Ab-
cam), ab4074 against alpha-tubulin (Abcam) and ab21685
against GRP78 (Abcam). Bands were visualised using
BMChemiluminescenceWestern Blotting Substrate (POD)
(Roche). Recombinant POLR3G and POLR3GL were pre-
pared as previously (2).
Cell proliferation assays
Cells were grown on 12-well plates, treated as described and
then stainedwith Trypan blue (Sigma-Aldrich) and counted
using a Neubauer’s haemocytometer.
Immunoprecipitation
Following treatment in 15 cm dishes, protein lysates were
prepared using CytoBuster Protein Extraction Reagent
(Merck Millipore) and incubated overnight with preim-
mune serum or antiserum 1900 against POLR3A (19) pre-
bound to Protein A magnetic beads (Pierce). Magnetic
beads were collected and washed twice with TBST con-
taining 0.5M NaCl and once with ultrapure water. Elution
was performed by incubating magnetic beads with 50 mM
glycine, pH 2 for 10 min. Eluates were neutralized with 1 M
Tris, pH 8.5 and analyzed by western blot.
Immunofluorescence
Cells were grown on round coverslips placed in 12-well
plates. Following treatments, the cells were washed twice
in PBS and fixed by addition of 4% paraformaldehyde for
20 min. Paraformaldehyde was removed by washing 3×
with PBS, then cells were permeabilised for 10 min in 0.2%
Triton-X-100. Following three washes in PBS, cells were
blocked for 15minwith PBS containing 1%BSA.Cells were
then incubated with antibody against Ki67 (ab15580, Ab-
cam) for 1 h, before three subsequent washes with PBS and
incubation with anti-rabbit Alexa Fluor 488 conjugated an-
tibody (Jackson Laboratories) for 30 min in the dark. Cov-
erslips were then washed 3× with PBS, allowed to air dry
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Table 1. Clinical details
Patient number
Patient
age PSA Operation MRI results
Diagnosis (two samples
per patient)
H627 67 7.7 Radical Prostatectomy Adjacent Normal
pT2a Gleason 7 (3+4)
H637 52 12.6 Radical Prostatectomy Adjacent Normal
pT3a Gleason 7 (3+4)
H643 78 3.4 Radical Prostatectomy Adjacent Normal
pT2c Gleason 7 (3+4)
H646 67 5.4 Radical Prostatectomy Adjacent Normal
pT3a Gleason 7 (3+4)
H455 67 0.2-0.4 Channel TURP for palliative
care of advanced disease
pT3b Gleason 9 (4+5)
Metastatic bone disease.
Table 2. Primers used for real-time PCR
Transcript Primers Accession no./locus
pre-tRNATyr FWD – CCTTCGATAGCTCAGCTGGTAGAGCGGAGG chr14:21128117-21128210
REV - CGGAATTGAACCAGCGACCTAAGGATCTCC
Chr16.tRNA1 FWD – ATACAGCCGCAGGGCC chr16:3200675-3200747
REV – CGTTAACATGGCAACGAC
Chr16.tRNA114 FWD – GGATCCTGTGGTGACCCA chr17:66016013-66016085
REV – CTAATCTCACGCGACCCAGATG
ARPP P0 FWD – GCACTGGAAGTCCAACTACTTC NM 001002.4
REV – TGAGGTCCTCCTTGGTGAACAC
CD55 FWD – GATGTACCTAATGCCCAGCCAGC NM 000574.4
REV – CATGAGAAGGAGATGGTTGCACC
CD59 FWD – AAGGAGGGTCTGTCCTGTTCGG NM 000611.5
REV – GGATGAAGGCTCCAGGCTGCT
CD63 FWD – GTGCAGTGGGACTGATTGCCGT NM 001257389.1
REV – GGGACTCGGTTCTTCGACATGG
Cytokeratin 8 (CK8) FWD – CGGAATGAATGGGGTGAG NM 001256282.1
REV – TGGTAGAGGCAGGAGTGGAG
Cytokeratin 14 (CK14) FWD – CCTCCTCCCAGTTCTCCTCT NM 000526.5
REV – ATCGTGCACATCCATGACC
Cytokeratin 18 (CK18) FWD – TGATGACACCAATATCACACGA NM 000224.3
REV – GGGCTTGTAGGCCTTTTACTTC
DR2 Alu FWD – CCTGAGGTCAGAAGTTCAAGACC Multiple loci
REV – GCAATGGCATGGTCTCAGCTC
Chr2.tRNA6 FWD – ACGCACTCTAGCCTGTGGT chr2:75124046-75124118
REV – ACTGGTTCCCTGACCAG
Chr2.tRNA20 FWD – CCTTTCAGCAGTTCCCATA chr2:131094701-131094772
REV – GCCACTTTTGTTCCCATACC
Chr1.tRNA84 FWD – TGTCACCAGCCCTCCCT chr1:161391883-161391954
REV - GCAAACTTCCCTGACCG
GRP78 FWD – GCTGAAGACAAGGGTACAGGGAAC NM 005347.5
REV – GGAGGGCCTGCACTTCCATAGA
NANOG-Alu-Sx FWD – GGGACTCGGTTCTTCGACATGG chr12; 7783172–7783477
REV – GGCTGATCTTGAACTCCCG
NANOG mRNA FWD – GATTTGTGGGCCTGAAGAAA NM 024865.4
REV – AAGTGGGTTGTTTGCCTTTG
Synaptophysin (SYP) FWD – CCAATCAGATGTAGTCTGGTCAGT NM 003179.2
REV – AGGCCTTCTCCTGAGCTCTT
Neuron specific FWD – CAATGTGGGGGATGAAGG NM 001975.3
enolase (NSE) REV – GTGTAGCCAGCCTTGTCGAT
POLR3G FWD – CACTTCGGCTGCAGAGTTTT NM 006467.3
REV – AGTGGGCAAATTCTGAAAG
POLR3GL FWD – AGAGCTACGAGGAGCCATGA NM 032305.3
REV – TTGTCTGAATAACGCTCCACA
POLR3A FWD – TCTGGAGACCTGTAGGGACAA NM 007055.4.
REV - CTGGCTCACCAATGCTCT
TERT FWD – GCCTTCAAGAGCCACGTC NM 198253.2
REV – CCACGAACTGTCGCATGT
TERC FWD – CGAGGTTCAGGCCTTTCA NR 001566.1
REV – CCACAGCTCAGGGAATCG
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and mounted on microscopic slides with mounting medium
containing DAPI (Cambridge Bioscience), for staining of
nuclei. Staining was visualised using an LSM 880 confocal
microscope (Zeiss) and analysed using Zen software.
Flow cytometry
Cells were washed with PBS and centrifuged at 200 g for
5 min. Cell pellets were then resuspended in Annexin-V-
FLUOS labeling solution (Roche) containing Annexin V
and propidium iodide stains. Analysis was performed us-
ing a CyAn ADP flow cytometer (Beckman Coulter) and
Summit software.
Cell viability assays
Cells were grown on 96-well plates and treated as described.
AlamarBlue reagent (Thermo Fisher) was then added di-
rectly to each well as 10% of the sample volume, incubated
at 37◦C for 30 min and fluorescence measured using a PO-
LARstar Optima microplate reader (BMG Labtech).
Matrigel invasion assay
Cells were plated onto Matrigel (BD Biosciences)-coated
8mfilters in 24-well plates. RPMI supplemented with 10%
foetal calf serum was used as a chemoattractant. Following
48 h treatment, cells that had invaded through the Matrigel
and filters were stained with DAPI and counted.
Chromatin Immunoprecipitation (ChIP) assays
Following treatment in 15 cm dishes, PC-3 cells were cross-
linked for 10 min with 1% formaldehyde. This reaction was
quenched with addition of 0.125 M glycine and incuba-
tion for 5 min. Cells were then washed, pelleted and resus-
pended in SDS lysis buffer. Sonication was performed using
a Bioruptor sonication device (Diagenode) to shear cross-
linked DNA into 200–1000 bp fragments. Protein/DNA
complexes were immunoprecipitated by overnight incuba-
tion at 4◦Cwith antibodies and then collected by incubation
with protein G agarose beads for 1 h at 4◦C with rotation.
Complexes were washed sequentially in low salt, high salt,
lithium chloride and TE wash buffers for 5 min each, be-
fore the protein/DNA complexes were eluted by incubation
with buffer containing 1% SDS and 0.1 M NaHCO3 for 30
min. Protein/DNA crosslinks were then reversed by incu-
bation in 200 mM NaCl at 65◦C for 4 h before DNA was
purified with ChIP DNA Clean and Concentrator columns
(Zymo Research). Purified DNA was analysed by quanti-
tative real-time PCR using primers GGGACTCGGTTC
TTCGACATGG andGGCTGATCTTGAACTCCCG for
NANOG-Alu-Sx or gene desert primers CATCCCTGGA
CTGATTGTCA and GGTTGGCCAGGTACATGTTT,
that amplify a site at 22646488 on chromosome 2 that is
46 kb from the nearest expressed sequence (20). Antibodies
used were 1900 against POLR3A (19,21), sc-47701 against
POLR2A (Santa Cruz Biotechnology), sc-28712 against
POLR3G (Santa Cruz Biotechnology), HPA027288 against
POLR3GL (Atlas Antibodies), ab3594 against H3K79me2
(Abcam) and sc-6571 against TAFI48 (Santa Cruz Biotech-
nology).
Patient-derived xenografts
Mouse work was approved by the University of York
Animal Procedures and Ethics Committee and per-
formed under a United Kingdom Home Office License
(POB5AE607). Rag2−/−C−/− mice were bred in the Bi-
ology Service facility, Department of Biology, University
of York. Mice used for xenografts were 6–8 weeks old and
housed in individually ventilated cages. Prostate tissue was
obtained, with informed written consent, from a patient
(H455) undergoing palliative channel TURP for advanced
CRPC. The resultant patient-derived xenograft was used at
the second generation in the experiments described here and
has been extensively validated (22). Fresh sample was cut
into 5-mm sections, mixed with 10% Matrigel at 4◦C (BD
Biosciences) and immediately implanted into the subcuta-
neous tissues of a Rag2−/−C−/− mouse. A tumour grew
with a latency of 302 days. With serial transplantation, the
mean latency is ∼70 days with a doubling time of 28 days.
To generate single cells from xenografts, tumours were
minced into small cubes (3 mm3) and incubated in RPMI
1640 (Invitrogen, Paisley, UK) containing 5% foetal calf
serum (FCS; Invitrogen) and collagenase type 1, at 200
IU/ml (Lorne Laboratories, Reading, UK) for 20 h at 37◦C.
Cells were washed in Dulbecco ‘A’ PBS (Oxoid Ltd, Bas-
ingstoke, UK) and disrupted further by trituration through
a 21 G blunt needle (Scientific Laboratory Supplies Ltd,
Hessle, UK). Cell suspensions were then incubated in 0.05%
trypsin/EDTA for 30 min at 37◦C, passed through 70-m
cell strainers and a Ficoll gradient (Ficoll-Paque Plus; GE
Healthcare Life Sciences, Little Chalfont, UK) to further
enrich for viable cells. Murine haematopoietic and mes-
enchymal cells were depleted by MACS (Mouse cell deple-
tion kit (Miltenyi Biotec).
Mouse-depleted tumour cells were treated for 48 h with
20 M ML-60218 or vehicle control. Viable cell numbers
were determined using trypan blue and equivalent numbers
injected subcutaneously into both flanks of 6- to 8-week-
oldmale Rag2−/−C−/− mice at limiting dilutions, together
with 2 × 105 irradiated STO feeder cells in Matrigel. The
mice were monitored until tumours reached 1.0 cm3. Pair-
wise tests and  2 tests to determine tumour initiation fre-
quencies were calculated using ELDA software (23).
RESULTS
POLR3G and POLR3GL have differential effects on
prostate cancer cells
Prostate epithelial cells are classified into luminal, basal and
neuroendocrine (NE) categories, each defined by expression
of canonical marker genes that are transcribed by pol II.
Depletion of POLR3G (Figure 1A) had minimal effect on
expression of the basal cell marker CK14, or the luminal
cell markers CK8 and CK18, but induced the NE markers
SYP and NSE (Figure 1B). Induction of CD55, CD59 and
CD63, which are detected in granules secreted by prostate
(24–27), is consistent with the abundance of neurosecretory
granules that characterise NE cells (15). In addition, we ob-
served induction of GRP78, which is associated with CRPC
(28). In contrast, a significant decrease was detected in ex-
pression of NANOG, a key regulator of pluripotency, stem
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Figure 1. Differential response of PC-3 cells toRNAi-mediated depletion of pol III subunits. (A)Western blot of POLR3Gand actin in PC-3 cells harvested
48 hrs after transfection with control or POLR3G-targeting siRNAs. (B) Mean relative changes in normalized expression of unprocessed pre-tRNATyr
and mRNAs encoding CK8, CK14, CK18, SYP, NSE, GRP78, CD55, CD59, CD63 and NANOG in PC-3 cells harvested 48 hrs after transfection with
control or POLR3G-targeting siRNAs, as determined by RT-qPCR in 3–4 independent experiments. (C) Western blot of POLR3GL and actin in PC-3
cells harvested 48 h after transfection with control or POLR3GL-targeting siRNAs. (D) Mean relative changes in normalized expression of unprocessed
pre-tRNATyr and mRNAs encoding CK8, CK14, CK18, SYP, NSE, GRP78, CD55, CD59, CD63 and NANOG in PC-3 cells harvested 48 hrs after
transfection with control or POLR3GL-targeting siRNAs, as determined by RT-qPCR in 3–4 independent experiments. (E) Mean PC-3 cell numbers over
3 days following transfection with control siRNA or siRNAs targeting POLR3G or POLR3GL, as indicated, in 5 independent experiments. (F) Western
blot of POLR3A and actin in PC-3 cells harvested 48 h after transfection with control or POLR3A-targeting siRNAs. (G) Mean relative changes in
normalized expression of unprocessed pre-tRNATyr and mRNAs encoding CK8, CK14, CK18, SYP, NSE, GRP78, CD55, CD59, CD63 and NANOG in
PC-3 cells harvested 48 hrs after transfection with control or POLR3A-targeting siRNAs, as determined by RT-qPCR in 3–4 independent experiments. (H)
Mean PC-3 cell numbers over 3 days following transfection with control or POLR3A-targeting siRNAs, as indicated, in three independent experiments. *
indicates P < 0.05 relative to control siRNA by t-test; ** indicates P < 0.01; *** indicates P < 0.005. Error bars represent S.E.M.
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cell self-renewal and proliferation (29–33). These data sug-
gest that POLR3G levels can influence differentiation of
prostate cancer cells, as reported previously in hESC. The
response is observed at a level of POLR3G depletion that
reduces expression of the primary pre-tRNATyr transcript,
a canonical pol III product, by ∼58% on average (Figure
1B).
The studies of POLR3G using hESC systems did not
investigate other pol III subunits. We tested how PC-3
cells respond to depletion of POLR3GL, the paralogue
of POLR3G. When POLR3GL was depleted by RNAi,
pre-tRNATyr was reduced by ∼48% on average (Figure
1C and D). Thus, both POLR3G and POLR3GL con-
tribute in PC-3 cells to the synthesis of tRNA, an es-
sential pol III product. This is consistent with evidence
that most pol III-transcribed genes can recruit either of
these subunits (3). In contrast to the similar tRNA re-
sponse, depletion of POLR3GL did not suppress expres-
sion of NANOG or induce the differentiation markers that
are activated when POLR3G is depleted (Figure 1D). Co-
immunoprecipitation confirmed that both paralogues asso-
ciate with the core pol III subunit POLR3A in PC-3 cells
(Supplementary Figure S1), consistent with the compara-
ble effects on pre-tRNA when either is depleted.
Cells generally stop dividing when induced to differenti-
ate. Indeed, PC-3 cell proliferationwas significantly reduced
by RNAi of POLR3G, but not of POLR3GL (Figure 1E).
Thus, selective depletion of POLR3G induces a switch from
proliferation to differentiation, an effect not observed when
the paralogous subunit POLR3GL is depleted to a simi-
lar extent. As synthesis of tRNATyr is comparably reduced
whether POLR3G or POLR3GL is depleted, the data sug-
gest that the trigger to differentiate is more specific than a
general decrease in total pol III output.
Although POLR3G is known to form part of the pol
III enzyme complex, the possibility exists that it has addi-
tional independent functions, as yet to be discovered. Prece-
dent is provided by aminoacyl-tRNA synthetases, many of
which perform non-canonical functions unrelated to their
catalytic activities (34). If POLR3G influences the balance
between differentiation and proliferation as part of pol III,
then it is likely to require POLR3A, the largest pol III sub-
unit that provides much of the catalytic site (35). Consistent
with this, RNAi-mediated depletion of POLR3A can also
induce differentiation markers and suppress proliferation
of PC-3 cells (Figure 1F–H). This suggests that the effect
of POLR3G on cell fate reflects its function as part of pol
III. Support for this conclusion is provided by use of ML-
60218, a small molecule inhibitor with high pol III speci-
ficity (36,37). At a concentration (20M) that decreases pre-
tRNATyr by ∼59%, similar to the siRNAs targeting pol III
subunits, ML-60218 stimulates expression of SYP andNSE
mRNAs, indicating that the NE differentiation programme
is triggered (Figure 2A). Induction was confirmed at the
protein level (Figure 2B). Dendritic processes that are char-
acteristic of NE cells were apparent after treatment with
20MML-60218 (Supplementary Figure S2). Proliferation
was also suppressed, as established by cell counts and stain-
ing for Ki67 (Figure 2C and D). Thus, a pol III-selective
transcriptional inhibitor can mimic the effects of pol III de-
pletion in inducing differentiation and decreasing prolifer-
ation of PC-3 cells.
Expression of telomerase provides a means to avoid the
erosion of telomeres that limits replication of normal so-
matic cells. Both the RNA (TERC) and protein (TERT)
components of telomerase decrease significantly in response
toML-60218 (Supplementary Figure S3). This is consistent
with its negative effect on proliferative activity and positive
influence on differentiation.
As POLR3G levels decrease when embryonic cells differ-
entiate (2,4,5), we investigated if this is also true for PC-3
cells treated with ML-60218. Indeed, POLR3G levels are
substantially lower after 48 h exposure to 20 M ML-
60218 (Figure 2E). This response is specific, as POLR3A
and POLR3GL show little or no change. Although there is
minimal change in POLR3GL abundance under these con-
ditions, co-immunoprecipitation suggests that stable associ-
ation of POLR3GL with the pol III core increases (Figure
2F), perhaps providing some compensation for loss of its
paralogue.
The data above support a model in which cell fate de-
cisions are influenced by pol III activity according to its
subunit composition: pol III that contains POLR3G sup-
presses differentiation and promotes proliferation, but pol
III does not have this effect when it incorporates POLR3GL
instead of POLR3G. If both forms are affected by RNAi
of the shared catalytic subunit POLR3A or treatment with
ML-60218, loss of POLR3G-dependent function triggers
the switch in cell fate that occurs when POLR3G itself is
depleted; this may reflect a dominance of POLR3G relative
to POLR3GL in PC-3 cells.
The most abundant pol III product is tRNA. RT-PCR
detects immature pre-tRNA, but not the processed tran-
scripts that are highly methylated and folded (38–40). Al-
though unprocessed pre-tRNAiMet levels decrease by 44%,
mature tRNAiMet falls by only 12% after exposure for 48 h
to 20 M ML-60218 (Figure 2G). Thus, steady-state lev-
els of mature tRNA can be relatively stable despite signif-
icant reductions in rates of production. This is consistent
with previous evidence that tRNA levels can be maintained
in differentiated cells despite decreased synthesis (41). These
data show that proliferative arrest and differentiation of PC-
3 cells can be induced by changes in pol III activity that have
only minor impact on the steady-state levels of its principle
products.
DR2Alu transcripts are differentially regulated by POLR3G
and POLR3GL
Additional templates transcribed by pol III include the
Alu short interspersed nuclear elements (SINEs). A sub-
set of the family, termed DR2, produces transcripts that
are processed by DICER into small repeat-induced RNAs
(riRNAs) that target specific mRNAs for degradation
(18,42). An important target that is regulated in this way
is NANOG, which controls stem cell regeneration (18,42).
Overexpression of DR2 Alus in hESC suppresses NANOG
and stem cell proliferation, whereas depletion of DR2 Alu
transcripts impairs differentiation (18,42). We therefore in-
vestigated whether the distinct effects of POLR3G and
POLR3GL on differentiation and proliferation might in-
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Figure 2. Response of PC-3 cells to pol III inhibitor ML-60218. (A) Mean relative changes in normalized expression of unprocessed pre-tRNATyr and
mRNAs encodingCK8, CK14, CK18, SYP,NSE,GRP78, CD55, CD59, CD63 andNANOG in PC-3 cells harvested 48 hrs after treatment with or without
20 M ML-60218, as determined by RT-qPCR in 3–6 independent experiments. (B) Western blot of NSE, SYP and tubulin in PC-3 cells harvested 48 h
after treatment with or without 20 M ML-60218. (C) Means of PC-3 cell numbers over 3 days with or without 20 M ML-60218, in six independent
experiments. (D) Means of the percentage of PC-3 cells staining positively for Ki67 proliferation marker 2 days after treatment with or without 20 M
ML-60218, in three independent experiments. (E) Western blot of POLR3A, POLR3G, POLR3GL and actin in PC-3 cells harvested 48 h after treatment
with or without 20 MML-60218. (F) Antiserum to POLR3A was used to immunoprecipitate pol III from PC-3 cells cultured for 48hrs without or with
20 MML-60218; panels show western blots of immunoprecipiated protein probed with antibodies to POLR3A, POLR3G and POLR3GL, as indicated.
(G) Representative northern blot of U2 snRNA (pol II-transcribed control), unprocessed pre-tRNAiMet and mature tRNAiMet in PC-3 cells harvested 48
hrs after duplicate treatment with or without 20 MML-60218. * indicates P < 0.05 relative to control by t-test; ** indicates P < 0.01; *** indicates P <
0.005. Error bars represent S.E.M.
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volve DR2 Alus. In support of this, DR2 Alu RNA lev-
els increase when POLR3G is depleted by RNAi, but are
unaffected by comparable depletion of POLR3GL (Fig-
ure 3A). NANOG mRNA responds in a reciprocal man-
ner (Figure 3B), consistent with its suppression by DR2
Alu riRNA (18,42). A member of the DR2 Alu family lies
∼6kb upstream of the NANOG gene and has been dubbed
NANOG-Alu-Sx; it is transcribed to produce RNAs that
are processed into riRNAs with high complementarity to a
region in the 3′-UTR of NANOG mRNA that mediates its
turnover (18). As with the DR2 Alu family in general (Fig-
ure 3A), expression of NANOG-Alu-Sx is unchanged by
depletion of POLR3GL but increases following RNAi of
POLR3G (Figure 3C). These data suggest that POLR3G
selectively exerts an inhibitory influence on expression of
DR2 Alu transcripts. This suppressive effect might in prin-
ciple involve obstruction of the promoter or transcribed re-
gion. Alternatively, the chromatin landscape might become
more conducive to DR2 Alu transcription as proliferation
slows and differentiation commences following depletion of
POLR3G.
BecauseML-60218 causes POLR3G levels to fall (Figure
2E), it might allow induction of NANOG-Alu-Sx. Indeed,
NANOG-Alu-Sx expression increases in response to ML-
60218 (Figure 3D). As this treatment inhibits pol III, we
postulated that the induced transcripts are synthesized by
pol II. Most RNAs that contain Alu sequences are thought
to be pol II products, as the pol III promoter is weak and/or
epigenetically repressed inmostAlu copies (43–49). In some
SINEs, pol III conducts basal transcription, but is replaced
by pol II to allow elevated expression in response to specific
stimuli (50). In support of this scenario, selective pol II inhi-
bition with low dose -amanitin suppresses the induction of
NANOG-Alu-Sx in response to ML-60218, whilst having
no effect on its basal expression in untreated cells (Figure
3E). ChIP confirmed the recruitment of pol II (POLR2A
catalytic subunit) to NANOG-Alu-Sx in the presence of
ML-60218, whilst the signal from pol III (POLR3A cat-
alytic subunit) decreases in parallel (Figure 3F). ChIP speci-
ficity was demonstrated using a ‘gene-desert’ locus free of
recognizable genes (Figure 3G). Pol II-transcribed regions
can be identified by methylation of histone H3 on lysine 79
(H3K79), a modification not associated with pol III activ-
ity (21). ChIP with antibody specific for methylated H3K79
showed induction of this mark at NANOG-Alu-Sx follow-
ing treatment with ML-60218. This provides evidence that
the pol II recruited to this site is active, as H3K79 is methy-
lated specifically by the pol II elongation complex during
transcription (51). These data can explain the expression of
NANOG-Alu-Sxwhen pol III is inhibited usingML-60218.
We conclude that pol II can replace pol III to transcribe
NANOG-Alu-Sx when POLR3G is depleted by RNAi or
ML-60218 treatment.
NANOG-Alu-Sx RNA can be processed into short
riRNA that targets NANOG mRNA for degradation
(18). Northern blots with strand-specific NANOG-Alu-Sx
probes detected an riRNA of ∼105 nts that is complemen-
tary to the 3′-UTR of NANOGmRNA (Figure 4A). Trans-
fection of a 33nt synthetic RNA corresponding to part of
this riRNA suppressed NANOG and induced expression of
differentiation markers (Figure 4B and C). These changes
in gene expression were not seen when the opposite strand
from the same region was transfected (Figure 4C and Sup-
plementary Figure S4). In addition, the NANOG-Alu-Sx
RNA fragment reduced cell proliferation (Figure 4D and
E). Synthetic RNAs corresponding to the DR2 Alu con-
sensus sequence can also suppress NANOGmRNA in PC-
3 cells, as shown previously in hESC (42); this is accom-
panied by induction of NE markers and reduced prolifer-
ation (Figure 4E–G). It therefore seems probable that riR-
NAs derived from multiple Alu loci can influence the bal-
ance between proliferation and differentiation in prostate
cancer cells. Nevertheless, a specific locus, NANOG-Alu-
Sx, is sufficient to generate riRNA that causes NANOG
mRNA degradation to trigger differentiation. Production
of this riRNA is suppressed by POLR3G, allowing prolif-
eration and self-renewal.
Prostate cancer cells show enhanced sensitivity toML-60218
We compared the PC-3 cancer cell line with PNT2C2, a
non-tumourigenic line of immortalized healthy prostate ep-
ithelium (52). The relative expression of mRNA encoding
POLR3A is higher in PC3 than in PNT2C2, but this dif-
ference is not reflected at the protein level (Figure 5A and
B). However, both mRNA and protein of POLR3G are
elevated in the cancer cells relative to the untransformed
cells. In contrast, levels of POLR3GL mRNA and protein
are similar between these prostate lines (Figure 5A, B and
Supplementary Figure S5). These observations are consis-
tent with previous evidence that cancer cells overexpress
POLR3G selectively (2,8). AlthoughML-60218 inhibits pol
III-dependent transcription in PNT2C2 cells, it does not in-
duce the differentiation markers that are induced in PC-3
cells (Figure 5C). Furthermore, exposure for three days to
20M ML-60218 has minimal effect on the rapid prolif-
eration of PNT2C2 cells, in contrast to PC-3 (Figure 5D).
The same is true for POLR3G depletion by RNAi (Figure
5E and F). The Alamar Blue assay, a measure of cellular
health and viability (53), also revealed far less sensitivity of
PNT2C2 to ML-60218 compared with PC-3 (Figure 5G).
This was confirmed by staining withAnnexin V and propid-
ium iodide, which showed that only the PC-3 cells display
increased apoptosis under these conditions (Supplementary
Figure S6). The relative tolerance of PNT2C2 cells to ML-
60218 does not reflect a compromised apoptotic pathway,
as a strong response is elicited by the alkaloid staurosporine
(Supplementary Figure S6). Thus, PC-3 cancer cells are sig-
nificantly more sensitive to pol III inhibition than untrans-
formed PNT2C2 cells.
Primary cells were cultured from the tumours of four pa-
tients withGleason grade 7 cancers, obtained during radical
prostatectomy. There was heterogeneity between patients in
the responses to treatment for 48 h with 20 MML-60218,
but pre-tRNATyr decreased by 36% on average, whereas
mRNA encoding the basal cell marker CK14 showed min-
imal change (Figure 6A). In tumours from two of the four
patients (H643 and H637), ML-60218 induced DR2 Alu
SINEs, including NANOG-Alu-Sx, and this was accom-
panied by suppression of NANOG mRNA. Alu induction
andNANOG repression was weaker than in PC-3 cells, per-
haps because the tumour biopsies included untransformed
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Figure 3. Effects of POLR3G RNAi and ML-60218 on DR2 Alu. (A) Mean relative changes in normalized expression of DR2 Alu RNA in PC-3 cells
harvested 48 hrs after transfection with control siRNA or siRNAs targeting POLR3G or POLR3GL, as determined by RT-qPCR in three independent
experiments. (B) Mean relative changes in normalized expression of NANOG mRNA in PC-3 cells harvested 48 h after transfection with control siRNA
or siRNAs targeting POLR3G or POLR3GL, as determined by RT-qPCR in three independent experiments. (C) Mean relative changes in normalized
expression of NANOG-Alu-Sx RNA in PC-3 cells harvested 48 h after transfection with control siRNA or siRNAs targeting POLR3G or POLR3GL,
as determined by RT-qPCR in three independent experiments. (D) Mean relative changes in normalized expression of NANOG-Alu-Sx RNA in PC-3
cells harvested 48 h after treatment with or without 20 M ML-60218, as determined by RT-qPCR in three independent experiments. (E) Mean relative
changes in normalized expression of NANOG-Alu-Sx RNA in PC-3 cells harvested 48 h after treatment with or without 20MML-60218, as determined
by RT-qPCR in 3 independent experiments. Black bars indicate samples that were exposed to 10g/ml -amanitin for 4 h prior to harvesting. (F) Mean
ratios relative to input of NANOG-Alu-Sx DNA immunoprecipitated using antibodies against POLR3A, POLR2A, H3K79me2 and TAFI48 (negative
control) with chromatin from PC-3 cells harvested 48 h after treatment with or without 20MML-60218, as determined by ChIP-qPCR in six independent
experiments. (G) Mean ratios relative to input of gene desert DNA immunoprecipitated using antibodies against POLR3A, POLR2A, H3K79me2 and
TAFI48 (negative control) with chromatin from PC-3 cells harvested 48 h after treatment with or without 20 MML-60218, as determined by ChIP-qPCR
in 6 independent experiments. * indicates P< 0.05 relative to control by t-test; ** indicates P< 0.01; *** indicates P< 0.005. # indicates P< 0.05 by t-test
for +-amanitin relative to –-amanitin. Error bars represent S.E.M.
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Figure 4. Effects of DR2 Alu RNA on differentiation and proliferation of PC-3 cells. (A) Northern blot of RNA harvested from PC-3 cells after 48 h
treatment with or without 20 MML-60218 and hybridized with probes for U2 snRNA (pol II-transcribed control) and each strand of NANOG-Alu-Sx
RNA. (B) Means of the relative changes in normalized expression of unprocessed pre-tRNATyr and mRNAs encoding CK8, CK14, CK18, SYP, NSE,
GRP78, CD55, CD59, CD63 and NANOG, as determined by RT-qPCR in 3–5 independent experiments, in PC-3 cells harvested 48 hrs after transfection
with a 33nt synthetic RNA corresponding to part of the NANOG-Alu-Sx sequence. (C)Western blot of NANOG and actin protein expression in PC-3 cells
48 h after mock transfection (control) or transfection with a 33nt synthetic RNA corresponding to forward or reverse strands of part of the NANOG-Alu-
Sx sequence. (D) Means of PC-3 cell numbers over 3 days following transfection with a 33nt synthetic RNA corresponding to part of the NANOG-Alu-Sx
sequence, as indicated, in 4 independent experiments. (E) Means of the percentage of PC-3 cells staining positively for Ki67 proliferation marker 48 h
after mock transfection or transfection with a 33nt synthetic RNA corresponding to part of the NANOG-Alu-Sx sequence or a 56nt synthetic RNA
corresponding to part of the DR2 Alu consensus sequence. (F) Means of the relative changes in normalized expression of unprocessed pre-tRNATyr
and mRNAs encoding CK8, CK14, CK18, SYP, NSE, GRP78, CD55, CD59, CD63 and NANOG, as determined by RT-qPCR in three independent
experiments, in PC-3 cells harvested 48 h after transfection with a 56nt synthetic RNA corresponding to part of the DR2 Alu consensus sequence. (G)
Means of PC-3 cell numbers over 3 days following transfection with a 56nt synthetic RNA corresponding to part of the DR2 Alu consensus sequence, as
indicated, in three independent experiments. * indicates P < 0.05 relative to control by t-test; ** indicates P < 0.01; *** indicates P < 0.005. Error bars
represent S.E.M.
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Figure 5. Benign PNT2C2 prostate cells express less POLR3G and are less sensitive to ML-60218 than PC-3 cells. (A) Normalized relative levels of
POLR3A, POLR3G and POLR3GLmRNAs in PNT2C2 and PC-3 cells, as determined by RT-qPCR in two independent experiments. (B) Western blot of
POLR3A, POLR3G, POLR3GL and actin proteins in PC-3 and PNT2C2 cells. (C) Means of the relative changes in normalized expression of unprocessed
pre-tRNATyr and mRNAs encoding CK8, CK14, CK18, SYP, NSE, GRP78, CD55, CD59, CD63 and NANOG in PNT2C2 cells harvested 48 hrs after
treatment with or without 20M ML-60218, as determined by RT-qPCR in three independent experiments. (D) Means of PNT2C2 cell numbers over 3
days in presence or absence of 20MML-60218, in three independent experiments. (E) Western blot of POLR3G and actin in PNT2C2 cells harvested 48
h after transfection with control or POLR3G-targeting siRNAs. (F) Means of PNT2C2 cell numbers over 3 days following transfection with control or
POLR3G-targeting siRNAs, as indicated, in three independent experiments. (G) Means of the percentage of viable PNT2C2 and PC-3 cells, as determined
using Alamar blue, after 2 days exposure to the indicated concentrations of ML-60218, in three independent experiments. * indicates P < 0.05 relative to
control by t-test; *** indicates P < 0.005. Error bars represent S.E.M.
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Figure 6. Primary cells from prostate tumours differentiate in response to ML-60218. (A) Relative changes in normalized expression of the indicated
transcripts, as determined by RT-qPCR, when tumour cells from patients H646, H643, H627 and H637 were treated for 48 h with or without 20 MML-
60218. Means are indicated by horizontal lines and values for each patient are indicated by symbols. (B) Normalized relative levels of POLR3A, POLR3G
and POLR3GL mRNAs in normal and cancer cells from patients H646, H643, H627 and H637, as determined by RT-qPCR. * indicates P< 0.05 relative
to normal by t-test. Error bars represent S.E.M. (C) Relative changes in expression of the indicated transcripts, as determined by RT-qPCR, when cells
from non-cancerous tumour-adjacent cells from patients H646, H643, H627 and H637 were treated for 48 h with or without 20 MML-60218. Means are
indicated by horizontal lines and values for each patient are indicated by symbols.
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contaminating cells. Nevertheless, these tumours showed in-
duction of CK8, CK18, GRP78, CD55, CD59 and CD63
mRNAs (Figure 6A). In general, SYP and NSE mRNAs
were also induced, but this was not the case for H643. This
suggests thatML-60218 triggered differentiation of tumour
H643 towards a luminal phenotype (demonstrated by CK8
andCK18markers) without the accompanyingNE features
indicated by SYP and NSE. In contrast, two tumours with-
out NANOG suppression (H646 andH627) still showed in-
duction of SYP and NSE, suggesting alternative pathways
towards NE properties. Thus, the secondary transcriptomic
changes caused byML-60218 vary between patients. This is
expected, given the individuality of genotype and molecu-
lar lesions in these cancers (54). Furthermore, the degree of
cell differentiation varied between regions of each tumour,
adding to heterogeneity between samples.
At the same time as these tumours were removed, adja-
cent healthy material was recovered from the same organs.
The samples of matched non-cancerous prostate were cul-
tured and treated in parallel to the tumours from the same
patients.Whereas POLR3A and POLR3GLwere expressed
at comparable levels, POLR3G expression was on average
3.7-fold higher in tumours relative to adjacent prostate sam-
ples from the same individuals (Figure 6B). There was again
heterogeneity between patients, with H627 showing much
weaker overexpression of POLR3G than the others (Sup-
plementary Figure S7). In these primary non-cancerous
cells, ML-60218 inhibited pre-tRNATyr by 40%, compara-
ble to the matched cancer cells (36% inhibition), but had
minimal effect on DR2 Alu, NANOG, CK8 or CK14 ex-
pression (Figure 6C).NSE,GRP78,CD55 andCD59 some-
times increased, but for each patient the response of the
non-cancerous prostate sample was weaker than that of the
tumour sample. Thus, as with the cell line models, normal
primary cells differentiate less readily than matched cancer
cells in response to ML-60218.
The pol III inhibitor slowed proliferation of both nor-
mal and cancer cells from the four patients (Figure 7A), al-
though cells from the tumours were significantly more sen-
sitive (P < 0.01 after 72 h). However, the viability of the
normal cells was almost unperturbed after 48 h exposure
to 20 MML-60218, whereas that of the tumour cells was
suppressed by 25% (Figure 7B). Higher concentrations of
ML-60218 do affect viability of the normal cells, but still
have a greater impact on the cancer cells. These data sug-
gest that oncogenic transformation enhances the sensitivity
of prostate cells to pol III inhibition, which may provide a
useful vulnerability.
ML-60218 can deplete tumour initiating cells
The cancer stem cell (CSC) hypothesis posits that tumours
contain tiny populations of long-lived, pluripotent stem
cells with the capacity for self-renewal and differentiation
into the various lineages of the tumour (55,56). CSC can
survive radiation or chemotherapy and then drive disease
recurrence leading to relapse after therapy (56). The fre-
quency of such tumour initiating cells in a heterogeneous
population can be estimated by engrafting into mice at lim-
iting dilutions (23,57). This xenograft assay was conducted
using androgen-independent tumour cells derived from a
patient with CRPC (22). Treatment for 48 h in culture with
20 M ML-60218 again induced differentiation markers
such as SYP,NSE andGRP78 (Figure 8A).Aswith the can-
cer cells from other patients, viability was compromised, in
this case by ∼23% (Figure 8B). This loss was taken into ac-
count when the cells were engrafted into mice, so that con-
trol and treatment arms received equal numbers of viable
human cells. Dilution series were engrafted into mice and
tumour development monitored. Exposure to ML-60218
was found to delay tumourigenesis significantly; for exam-
ple, a mean latency period of 75 days after injection of 105
viable untreated cells was extended to 100 days when the
cells were pre-treated for 48 h with 20 MML-60218 (Fig-
ure 8C). Furthermore, pairwise tests showed a significant
decrease in the frequency of tumour initiation (P < 0.05)
and that the percentage of cells forming tumours was re-
duced by ∼4-fold (Figure 8D). Once initiated, the tumours
grew at similar rates in the absence of drug, in contrast to
the impaired proliferation observed in its presence (Figure
7A). Nevertheless, the data indicate that transient exposure
to ML-60218 can have selective and enduring effects on tu-
mour initiating activity, consistent with CSC depletion.
DISCUSSION
Many studies have described links between pol III and can-
cer (e.g. (8,58–76)}; reviewed by (77–81)). Most relevant
to the current work are reports that POLR3G overexpres-
sion can have oncogenic effects in cultured cells and mice
(2,6). Conversely, RNAi of POLR3G causes differentiation
of hESC (5,7). We found that prostate cancer cells also dif-
ferentiate when depleted of POLR3G, either by RNAi or
by treatment with ML-60218. The resultant differentiation
is likely to involvemultiple changes in transcript expression,
but can be mimicked simply by overexpressing riRNA that
is suppressed by POLR3G and in turn controls levels of the
pluripotency factor NANOG (Figure 4). POLR3G expres-
sion may be amplified by positive feedback, as NANOG
binds and activates the gene encoding POLR3G (5), sta-
bilizing the undifferentiated state (Figure 9). Such a sce-
nario is consistent with evidence that hESC overexpressing
POLR3G are resistant to differentiation signals (5,7).
RiRNAs that target NANOG are produced by DICER-
dependent processing of transcripts containingDR2Alu se-
quences (18,42). Such transcripts are made predominantly
by pol III in hESC (18,42), but Alu SINEs are also com-
monly expressed by pol II as part of larger transcripts (47).
These properties reflect SINE generation by retrotranspo-
sition and random insertion, often near or within pol II-
transcribed genomic regions. Both pol II and pol III can be
detected at the NANOG-Alu-Sx and expression increases
when pol II replaces pol III (Figure 3). Precedent for such
behaviour comes from the B1-X35S subfamily of B1 SINEs,
the rodent equivalent of Alu, where pol III mediates basal
transcription but can be replaced by pol II to raise ex-
pression (50). This property allows B1-X35S to be induced
by aryl hydrocarbon receptor and it is noteworthy that
NANOG-Alu-Sx also contains a functional binding site for
this activator (18). In addition, NANOG-Alu-Sx contains
the DR2 motif that mediates Alu induction by retinoic acid
receptors (18,42). Such response elements allow regulatory
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Figure 7. Primary cells from prostate tumours are more sensitive to ML-60218 than adjacent non-cancerous cells from the same tissues. (A) Means of cell
numbers from tumours (left) and non-cancerous tumour-adjacent samples (right) from patients H646, H643, H627 and H637 during culture for 3 days
in the presence or absence of 20 M ML-60218. (B) Means of the number of viable cells, as determined using alamar blue, after 2 days of exposure of
tumour samples (left) and non-cancerous tumour-adjacent samples (right) from patients H646, H643, H627 and H637 to the indicated concentrations of
ML-60218, in three independent experiments. * indicates P < 0.05 relative to control by t-test; ** indicates P < 0.01; *** indicates P < 0.005. Error bars
represent S.E.M.
stimuli to control transcription of Alu subsets. Indeed, ex-
pression of individual Alu loci varies considerably between
cell types and growth conditions (82).
Depletion of POLR3G impacts cell behaviour in ways
that are not seen when POLR3GL is depleted. This is con-
sistent with the finding that overexpression of POLR3G
enhances the ability of partially transformed human fi-
broblasts to form anchorage-independent colonies, an ef-
fect not seen with POLR3GL (2). A simple hypothesis is
that these paralogous subunits mediate production of tran-
scriptomes that differ in some crucial way(s), although they
probably overlap substantially. Indeed, patterns of tRNA
expression vary markedly between proliferating and dif-
ferentiating cells (71). Although clear differences were not
seen in vitro between purified pol III containing POLR3G
or POLR3GL, levels of some pol III transcripts were
selectively increased in fibroblasts by overexpression of
POLR3G (2). For example, tRNAiMet levels increased when
POLR3G was overexpressed, but tRNAGlu did not (2). De-
pletion of POLR3G from hESC also had differential effects
on individual pol III products (5). A role in target discrim-
ination is consistent with the location of POLR3G/GL in
a module that interfaces between the catalytic core of pol
III and promoter-bound transcription factors (83–85). Sol-
vent exposed residues (85) may allow contacts with regu-
lators that distinguish between the paralogues, potentially
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Figure 8. Transient exposure toML-60218 can diminish tumour initiation in vivo. (A) Relative changes in normalized expression of the indicated transcripts,
as determined by RT-qPCR, when dissociated tumour cells from CRPC patient H455 were treated for 48 hrs with or without 20 M ML-60218. (B)
Percentages of viable cells, as determined using alamar blue, after 2 days exposure of H455 tumour samples to the indicated concentrations of ML-60218.
(C) Growth rates of tumours, following injection of 105 H455 cells pre-treated for 48 hrs with (triangles) or without (circles) 20 MML-60218 (n= 4 mice
per group). The relative value of 100% refers to a volume of ∼50 mm3. (D) Numbers of mice developing tumours after groups of four mice were injected
subcutaneously with the indicated numbers of viable H455 tumour cells after 48 h pre-treatment without (con) or with (test) 20 MML-60218. Calculated
tumour initiation frequencies and percentages of tumour-forming cells are shown for treatment and control arms.
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Figure 9. Model to explain the observed response of prostate cancer cells
to POLR3G depletion following RNAi or ML-60218 treatment. Undif-
ferentiated cells express NANOG, which has been shown to bind the
promoter of the POLR3G gene and stimulate its expression. Pol III as-
sociated with POLR3G binds DR2 Alu SINEs but does not transcribe
them efficiently. When POLR3G is depleted by RNAi or treatment with
ML-60218, levels of pol III at DR2 Alu SINEs decrease whereas levels
of pol II increase; transcription of these loci rises, generating transcripts
that are processed by dicer into repeat-induced small RNAs (riRNA) that
target NANOG mRNA for AGO-mediated degradation; falling levels of
NANOG trigger differentiation.
mediating differential recruitment and/or activity of pol III.
When ChIP-Seq was used to compare binding sites in fi-
broblasts, the large majority of loci occupied by POLR3G
were also occupied by POLR3GL and vice versa, but rela-
tive enrichment for one or other paralogue was observed at
a subset of genes (3). Consistent with this, both paralogues
can be detected at NANOG-Alu-Sx in PC3 cells (Supple-
mentary Figure S8). Nevertheless, expression of DR2 Alu
RNAs in PC3 cells responds to depletion of POLR3G, but
not POLR3GL (Figure 3A). Examples have been detected
where loci are bound by pol III but apparently not tran-
scribed (46). A parsimonious model is that pol III activity
at DR2 Alus is sensitive to whether it contains POLR3G
or POLR3GL, perhaps due to selective interaction(s) with
regulators. Expression is enhanced when pol III is replaced
by pol II, which can respond more strongly to activators,
a switch that can be triggered by selective depletion of
POLR3G.
A variety of tRNA fragments have been shown to influ-
ence cell proliferation and/or viability (86). These include
tRFs and SHOT-RNAs, which can stimulate proliferation
in prostate cancer cells (87,88). However, rates of tRNA
synthesis do not control levels of tRNA fragments, which
are dictated by the cleavage reactions and do not correlate
with expression of full-length tRNA (86,88,89). It therefore
seems unlikely that tRNA fragments contribute substan-
tially to the observed responses to POLR3G depletion, al-
though their involvement cannot be excluded. Other pol III
products might also be involved, such as NDM29 and/or
45A ncRNAs (58,59). Furthermore, the secondary effects
downstream of inhibiting any RNA polymerase are likely
to be diverse. Nevertheless, our ability to reproduce much
of the response using synthetic versions of Alu riRNAs that
are induced by ML-60218 suggests that Alu-mediated ef-
fects can provide a key component of the phenotype elicited
when pol III is inhibited in prostate cells.
There is a clinical need for more effective interventions
against CRPC (15). As well-differentiated tumours gen-
erally have better prognosis and POLR3G depletion trig-
gers differentiation of hESC, we hoped it might have sim-
ilar effects in a model of advanced disease. Indeed, RNAi
of POLR3G reduces proliferation and triggers differentia-
tion and/or death of PC-3 cells, whereas benign PNT2C2
prostate cells are less sensitive, despite lower POLR3G
expression. This differential response is reproduced using
ML-60218, a cell-permeable small molecule that inhibits
pol III and triggers selective depletion of POLR3G. Al-
though the possibility of off-target effects cannot be ex-
cluded, the fact that differentiation and proliferation re-
spond in the same way to ML-60218 as to siRNAs against
POLR3A and POLR3G provides confidence that the phe-
notype is mediated through pol III.
The response involves a specific decrease in expression
of the pluripotency marker NANOG, which suggests that
CSC are depleted. Support for this comes from measure-
ments of tumour initiation frequency in vivo using cells de-
rived from aCRPCpatient. Limiting dilutions allowed us to
estimate that 0.04% of patient-derived cells were capable of
seeding a new tumour in our xenograft model (Figure 8D).
This subpopulation with CSC activity is considered to be
responsible for disease recurrence and relapse after therapy
(13,56). Ex vivo exposure toML-60218 reduced tumour ini-
tiation frequency ∼4-fold when the cells were grafted back
into mice. These data provide functional evidence that ML-
60218 is not only effective against the bulk population of
tumour cells from a CRPC patient, but can also impair the
initiation of new tumours by CSCs that carry the greatest
threat to prognosis.
In other mammalian cell types, specific tRNAs have been
found to promote migration and invasion in culture, as
well as metastasis in mice (73–75). For example, migra-
tion of fibroblasts and melanoma cells can be stimulated
by tRNAiMet (73,74). As tRNAiMet expression in PC-3 cells
is reduced by ML-60218 (Figure 2G), we tested whether
their invasive behaviour is affected. Indeed, the ability of
PC-3 cells to invade matrigel is suppressed significantly by
treatment with ML-60218 (Supplementary Figure S9). In
breast cancer cells, invasion and metastasis is promoted by
tRNAGluUUC and tRNAArgCCG (75). We found that PC-3
cells express several genes encoding these tRNAs and that
levels of their primary transcripts decrease significantly in
response to ML-60218 (Supplementary Figure S10). These
data support the possibility that partial pol III inhibition
might reduce cancer spread. Effects on protein synthesis
and cell growth are also likely (77,79).
Since pol III is an essential enzyme, its targeting raises
concerns about general toxicity. However, sensitivity varies
according to cell type. This was clearly illustrated in ze-
brafish by a hypomorphic mutation in the POLR3B subunit
of pol III (90). Despite global decreases in tRNA levels to
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∼40% of wild-type, defects only appeared in highly prolif-
erative tissues, such as intestine and exocrine pancreas (90).
Human pancreatic adenocarcinoma lines are more sensi-
tive to ML-60218 than untransformed pancreatic epithelial
cells (91). Similarly, the benign prostate lines PNT2C2 and
BPH1 tolerate ML-60218 better than the PC-3 and DU145
prostate cancer cell lines (Figure 5 and Supplementary Fig-
ures S6 and S11) and primary cells from tumours are signif-
icantly more sensitive than non-cancerous cells from else-
where in the same prostates (Figure 7). Although these adja-
cent cells appear normal, theymay carry some of the genetic
and/or epigenetic changes responsible for the tumour that
necessitated prostatectomy (13). We therefore also tested
primary prostate epithelial cells from an organ donor, pre-
sumed to be cancer-free. Two days treatment with 20 M
ML-60218 had minimal effect on viability or expression of
differentiation markers in these cells, despite efficiently sup-
pressing pre-tRNA (Supplementary Figure S12). Collec-
tively, the data point towards a therapeutic window, where
cancer cells aremore sensitive than healthy cells to depletion
of pol III transcripts. The differential response may reflect
levels of POLR3G,which ismore abundant in tumours than
in normal cells (Figure 6B). If so, the restricted expression
and influence on pluripotency of POLR3G (2,4,5) suggest
that pol III may provide a vulnerability where tumours can
be attacked.
However, in considering pol III as a candidate drug target
for prostate cancer, some potentially unfavourable features
of the response to ML-60218 should be weighed against
the benefits listed above. One concern is the induction of
GRP78, a feature of aggressive variant prostate cancer
with NE differentiation that is linked with poor progno-
sis (28,92). ML-60218 also induces CD55, which has been
found to promote prostate cancer growth and survival (93).
CD55 and GRP78 are themselves considered attractive tar-
gets for therapies directed against cell surface molecules
(92,94); such approaches might be considered in combina-
tion with pol III inhibition. Another concern is that differ-
entiation occurs towards an NE phenotype, which is gen-
erally associated with low survival (15,95). Indeed, transd-
ifferentiation to an NE phenotype is an important mech-
anism of acquired resistance to treatments that target the
androgen receptor (15,96). However, one tumour (H643)
showed induction of luminal markers (CK8 and CK18)
without the NEmarkers SYP andNSE (Figure 6). This dis-
tinct response was still associated with increased DR2 Alu
RNA, suppression of NANOGmRNA and slowing of pro-
liferation. It is unclear why this individual responded differ-
ently from the others, but he may indicate the existence of
a subgroup that would benefit from the effects of treatment
on tumour cell viability, differentiation and proliferation,
without the potential hazards of NE induction. More ex-
tensive studies will be required to establish the prevalence
of such a hypothetical subgroup or whether this case is an
exceptional outlier.
CONCLUSIONS
In summary, this study demonstrates that the inhibitory ef-
fect of POLR3G on cell differentiation, first discovered in
hESC, is also a feature of prostate cancer cells. Although
this property is not shared by its paralogue POLR3GL, it
can be reproduced by depleting or inhibiting the pol III
catalytic subunit POLR3A. We interpret this to mean that
the influence of POLR3G on differentiation is mediated
through pol III, as opposed to some hypothetical pol III-
independent function. This influence can be explained, at
least in part, by the ability of POLR3G to regulate ex-
pression of DR2 Alu SINEs, which themselves control lev-
els of the pluripotency factor NANOG, through a post-
transcriptionalmechanism. SyntheticDR2AluRNA is suf-
ficient to trigger differentiation in the PC-3 model. The
cell-permeable small molecule ML-60218 inhibits pol III
and causes differentiation, POLR3G depletion, and signif-
icant reductions in the proliferation, invasiveness, tumour-
initiating activity and viability of prostate cancer cells. Un-
transformed cells appear to be less sensitive, raising the pos-
sibility of a therapeutic opportunity, if drugs can be devel-
oped with sufficient potency. Stratification might be neces-
sary, through appropriate biomarkers, to identify tumours
that differentiate towards luminal rather than NE pheno-
types. It is also worth exploring how other cancer types re-
spond to this approach.
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